Onward Medical’s Arc-EX spinal cord stimulator saw its first U.S. sales in late December, according to a Jan. 9 news release.
Seattle-based University of Washington Medicine and Next Steps Chicago were among the first commercial U.S. sales. Arc-EX earned de novo classification in December and is the first FDA-approved technology that is indicated to improve hand strength in people with spinal cord injuries.
Onward Medical is seeking a CE mark from the European Union for Arc-EX in 2025 along with a commercial launch abroad.
Investment firm Viscogliosi Brothers completed its acquisition of Stryker’s U.S. spine business, according to an April 1 news release. The…
Richard Mueller is the new president and CEO of Life Spine, according to an April 1 news release. Mr. Mueller…
Stryker CEO Kevin Lobo’s total compensation grew from $20.8 million in 2023 to just under $22 million in 2024, according…
Comments are closed.